156 related articles for article (PubMed ID: 2647289)
1. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes.
Geiser AG; Anderson MJ; Stanbridge EJ
Cancer Res; 1989 Mar; 49(6):1572-7. PubMed ID: 2647289
[TBL] [Abstract][Full Text] [Related]
2. Modulation of differentiation in PA-1 human teratocarcinoma cells after N-ras oncogene-induced tumorigenicity.
Tainsky MA; Yim SO; Krizman DB; Kannan P; Chiao PJ; Mukhopadhyay T; Buettner R
Oncogene; 1991 Sep; 6(9):1575-82. PubMed ID: 1681491
[TBL] [Abstract][Full Text] [Related]
3. Rapid induction of an experimental metastatic phenotype in first passage rat embryo cells by cotransfection of EJ c-Ha-ras and c-myc oncogenes.
Storer RD; Allen HL; Kraynak AR; Bradley MO
Oncogene; 1988 Feb; 2(2):141-7. PubMed ID: 3285293
[TBL] [Abstract][Full Text] [Related]
4. Growth in culture and tumorigenicity after transfection with the ras oncogene of liver epithelial cells from carcinogen-treated rats.
Braun L; Goyette M; Yaswen P; Thompson NL; Fausto N
Cancer Res; 1987 Aug; 47(15):4116-24. PubMed ID: 2440558
[TBL] [Abstract][Full Text] [Related]
5. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
[TBL] [Abstract][Full Text] [Related]
6. Suppression of tumorigenicity in somatic cell hybrids does not involve quantitative changes in transcription of cellular Ha-ras, Ki-ras, myc, and fos oncogenes.
Schäfer R; Geisse S; Willecke K
J Cell Biochem; 1987 May; 34(1):31-8. PubMed ID: 3584261
[TBL] [Abstract][Full Text] [Related]
7. Tumorigenicity of human HT1080 fibrosarcoma X normal fibroblast hybrids: chromosome dosage dependency.
Benedict WF; Weissman BE; Mark C; Stanbridge EJ
Cancer Res; 1984 Aug; 44(8):3471-9. PubMed ID: 6744274
[TBL] [Abstract][Full Text] [Related]
8. Suppression of the metastatic phenotype of a mouse skin carcinoma cell line independent of E-cadherin expression and correlated with reduced Ha-ras oncogene products.
Caulín C; López-Barcons L; Gonzáles-Garrigues M; Navarro P; Lozano E; Rodrigo I; Gamallo C; Cano A; Fabra A; Quintanilla M
Mol Carcinog; 1996 Feb; 15(2):104-14. PubMed ID: 8599577
[TBL] [Abstract][Full Text] [Related]
9. Role of chromosome loss in ras/myc-induced Syrian hamster tumors.
Oshimura M; Koi M; Ozawa N; Sugawara O; Lamb PW; Barrett JC
Cancer Res; 1988 Mar; 48(6):1623-32. PubMed ID: 2449958
[TBL] [Abstract][Full Text] [Related]
10. Suppression of tumorigenicity in somatic cell hybrids. II. Human chromosomes implicated as suppressors of tumorigenicity in hybrids with Chinese hamster ovary cells.
Klinger HP; Shows TB
J Natl Cancer Inst; 1983 Sep; 71(3):559-69. PubMed ID: 6577230
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the tumor suppressor activity of the K-rev-1 gene in human tumor cell lines.
Sato KY; Polakis PG; Haubruck H; Fasching CL; McCormick F; Stanbridge EJ
Cancer Res; 1994 Jan; 54(2):552-9. PubMed ID: 8275494
[TBL] [Abstract][Full Text] [Related]
12. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
13. Transforming and oncogenic potential of activated c-Ha-ras in three immortalized human breast epithelial cell lines.
Wang B; Soule HD; Miller FR
Anticancer Res; 1997; 17(6D):4387-94. PubMed ID: 9494538
[TBL] [Abstract][Full Text] [Related]
14. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.
Su ZZ; Austin VN; Zimmer SG; Fisher PB
Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744
[TBL] [Abstract][Full Text] [Related]
15. Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells.
Geiser AG; Der CJ; Marshall CJ; Stanbridge EJ
Proc Natl Acad Sci U S A; 1986 Jul; 83(14):5209-13. PubMed ID: 3523486
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
Spandidos DA
Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595
[TBL] [Abstract][Full Text] [Related]
17. Ha-Ras-1 oncogene dosage differentially affects Balb/3T3 cells' growth factor requirement and tumorigenicity.
Kovary K; Armelin MC; Armelin HA
Oncogene Res; 1989; 4(1):55-64. PubMed ID: 2654813
[TBL] [Abstract][Full Text] [Related]
18. Activated Val-12 ras p21 in cell culture fluids and mouse plasma.
Hamer PJ; La Vecchio J; Ng S; DeLellis R; Wolfe H; Carney WP
Oncogene; 1991 Sep; 6(9):1609-15. PubMed ID: 1923528
[TBL] [Abstract][Full Text] [Related]
19. Increased protein kinase C alpha expression in human colonic Caco-2 cells after insertion of human Ha-ras or polyoma virus middle T oncogenes.
Delage S; Chastre E; Empereur S; Wicek D; Veissiére D; Capeau J; Gespach C; Cherqui G
Cancer Res; 1993 Jun; 53(12):2762-70. PubMed ID: 8504416
[TBL] [Abstract][Full Text] [Related]
20. ras-induced neoplastic transformation and sensitivity to tumor necrosis factor.
Fernandez A; Chen PW; Ananthaswamy HN
Anticancer Res; 1994; 14(6B):2649-52. PubMed ID: 7872696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
